930d090f1d646a472181407ad59ad387fd8e4b5921711bd169b69a35f19bfd19

c5ae48646eb13ae5d043faddcc356b3a8e42aa3acbd6553eb52986214a75a68e

Cash and cash equivalents (USD, thousands)

Total assets (USD, thousands)

Royalty sale liability (USD, thousands)

Convertible notes, net of issuance costs (USD, thousands)

Common stock (USD, thousands)

Accumulated deficit (USD, thousands)

Total stockholders’ deficit (USD, thousands)

f557cdff915838425eb73712307ddcd30fef811a5f8cb3c8004aad474c4afa60

The significant drop in cash during Q4 2023 was primarily driven by substantial net cash used in operating activities. **Operating costs**—including expenses related to the commercialization of NEXLETOL and NEXLIZET as well as ongoing research and development—resulted in net cash outflows totaling **$(135.5) million** in 2023, which was only partially offset by cash inflows from **investing activities** (**$42.5 million**) and **financing activities** (**$50.5 million**).  **[0001628280-24-007066_espr-20231231.htm:153]** **[0001628280-24-007066_espr-20231231.htm:183]**  This aggregate effect led to a reduction in cash and cash equivalents from **$124.8 million** at the end of 2022 to **$82.2 million** in Q4 2023.  **[0001628280-24-007035_q42023earningspressrelease.htm:5]** **[0001628280-24-007066_espr-20231231.htm:181]** **[0001628280-24-007066_espr-20231231.htm:159]** 

Why did cash drop so significantly in Q4 2023?

The surge in cash in Q1 2024 was primarily driven by **net cash provided by operating activities**, which included strong net product sales and a **$100 million litigation-related settlement** from Daiichi Sankyo Europe, along with **net cash provided by financing activities** through the issuance of common stock that raised over **$90 million**. Additionally, the company incurred only minimal cash outflow from investing activities, which further contributed to the overall increase in cash and cash equivalents.  **[0001628280-24-020841_q12024earningspressrelease.htm:2]** **[ESPR_3386772_1]** **[0001628280-24-020862_espr-20240331.htm:4]** 

What factors contributed to the surge in cash in Q1 2024?

The substantial increase in total assets in Q1 2024 was primarily driven by a **significant surge in cash and cash equivalents**. This surge resulted from a **$100 million litigation-related settlement** and **$90.7 million in net proceeds from an underwritten public offering**, which boosted cash from **$82,248 thousand** to **$226,609 thousand**. Additionally, **increases in accounts receivable** (from **$48,494 thousand** to **$54,612 thousand**) and **inventories** (from **$65,623 thousand** to **$73,095 thousand**) also contributed to the overall growth in total assets.  **[ESPR_3386772_1]** **[0001628280-24-020841_q12024earningspressrelease.htm:2]** **[0001628280-24-020862_espr-20240331.htm:2]** 

What drove the substantial increase in total assets in Q1 2024?

The total assets declined from **$373,060 thousand** in Q1 2024 to **$314,114 thousand** in Q3 2024.  **[0001628280-24-020862_espr-20240331.htm:2]** **[0001628280-24-046307_espr-20240930.htm:2]**  However, the documents do not provide any explicit details or reasons for this decline.

Why did total assets decline from Q1 2024 to Q3 2024?

39ce4124dd8fcda12da018495ea07ea668d2bcc76441925ee57dbfe925ea9f2b

661eda1180fbcea46e36674b1df2a32a944edf9413a9bd36a304b67e1dd3ffef

Net loss [USD, thousands]

Non-cash royalty revenue [USD, thousands]

Depreciation expense [USD, thousands]

Amortization of debt issuance costs [USD, thousands]

Non-cash interest expense related to the revenue interest liability [USD, thousands]

Stock-based compensation expense [USD, thousands]

Net cash provided by (used in) operating activities [USD, thousands]

Purchase of property and equipment [USD, thousands]

Net cash (used in) provided by investing activities [USD, thousands]

Payment of royalty sale liability issuance costs [USD, thousands]

Net cash provided by financing activities [USD, thousands]

Net increase (decrease) in cash and cash equivalents [USD, thousands]

Accounts receivable [USD, thousands]

Prepaids and other assets [USD, thousands]

Deferred revenue [USD, thousands]

Inventories [USD, thousands]

Accounts payable [USD, thousands]

Other accrued liabilities [USD, thousands]

Cash and cash equivalents at beginning of period [USD, thousands]

Cash and cash equivalents at end of period [USD, thousands]

174694466d89e51c78afe7bffff9e04ac152fd94d76be5301a27a436046ded97

Product sales, net (USD, thousands)

Collaboration revenue (USD, thousands)

Total Revenues (USD, thousands)

Cost of goods sold (USD, thousands)

Research and development (USD, thousands)

Selling, general and administrative (USD, thousands)

Total operating expenses (USD, thousands)

Income (loss) from operations (USD, thousands)

Interest expense (USD, thousands)

Other income, net (USD, thousands)

Net income (loss) (USD, thousands)

Net income (loss) per common share - basic (USD)

Net income (loss) per common share - diluted (USD)

Weighted-average shares outstanding - basic (thousands)

Weighted-average shares outstanding - diluted (thousands)

Comprehensive income (loss) (USD, thousands)

e871bac92ed68069cfafba5c539b9c27685d6e468cee7691e05ebe8c7058e4da

Product Sales

Collaboration Revenue

Total Revenue

061e80010a2c36e2db8a3295fe93c662c081a0e483f0df859b24e54fb257a929

- NEXLETOL & NEXLIZET

- Collaboration Revenue

8fad273e0985211d9290f8fb15f75ef6ecec7f816a2f789f75fbe83998dd001f

Esperion Therapeutics Inc (ESPR)

Financials